Report: Bioprocessing trends 2018-2023

By Flora Southey

- Last updated on GMT

(Image: Getty/denizbayram)
(Image: Getty/denizbayram)

Related tags CAR-T Continuous manufacturing

Increased cell and gene therapy production and reduced development timelines are listed among bioprocessing trends predicted over the next five years, says consultant.

According to Mike Ultee of Ulteemit Bioconsulting, the bioprocessing industry should prepare for a number of growing trends in the development and manufacture of biologics. Among the predictions, cited in the CPhI Worldwide Annual Report, are improved productivity of fusion proteins and enzymes, and the rise of continuous bioprocessing.

Chimeric antigen receptor (CAR) T-cell therapy pipelines will continue to advance towards commercialisation, said Ultee.

“In five years’ time, we will have been through a golden period, with game-changing improvements made in upstream, downstream and continuous bioprocessing.

“The market will by then also boast much greater numbers of biosimilars and new applications for cell and gene therapies. The industry is collectively maturing extremely quickly from big pharma and biosimilars to contract development and manufacturing organisations (CDMOs),” ​he added.

Related news

Related products

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...